BRCA1 and cancer: In conjunction, the Supreme Court of the United States overturned Myriad Genetics’ patent on the BRCA1 and BRCA2 genes, which allowed for the development of multi-gene cancer predisposition panels that today are offered by multiple commercial companies [3].